Dermatology To Become A Key Franchise For Incyte
Topical Formulation Of Ruxolitinib On Fast Track For Vitiligo
Having just launched Opzelura in the US for atopic dermatitis, the US biotech is hoping for another approval in the next few months for its topical JAK inhibitor, this time for vitiligo.
